Fosun Pharma's Transfer Of Claimed Stake Investment Raises Questions
This article was originally published in PharmAsia News
Rumors are circulating that Fosun Pharma fell victim to Huixin Biotech Pulp's accounting fraud in 2008 and that Fosun was cheated out of RMB 188 million
You may also be interested in...
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
With Roche's oral spinal muscular atrophy therapy Evrysdi off to a strong start after its recent US launch, Novartis is switching its priorities for rival RNA-splicing drug branaplam and putting it into a Phase IIb trial for Huntington's disease.
Nuvation started in 2018 and raised a $275m series A round in 2019. Now it is merging with the EcoR1 Capital-sponsored SPAC Panacea Acquisition Corp. and raising $500m in equity capital.